Fortis Healthcare Targets 25% EBITDA Margin By FY28 And Approves ₹252 Crore CapEx

Market snapshot: Fortis Healthcare has maintained its FY27 consolidated margin guidance while outlining a clear roadmap to hit 25% EBITDA margins by FY28. This growth strategy is anchored by key operational improvements, the ramp-up of new units, a ₹252 crore Proton therapy facility in Gurugram, and the addition of 400 beds in the remaining quarters of FY27.

Data Snapshot

• Fortis reported Q1 FY27 consolidated revenue of ₹2,545 crore, representing a year-on-year growth of 17.5%.
• Operating EBITDA stood at ₹568 crore for Q1 FY27, supported by steady pricing and hospital parameters.
• A total CapEx of ₹252 crore has been approved for establishing a dedicated Proton therapy oncology facility at its Gurugram hospital.
• The hospital business is on track to operationalize 400 additional beds during the remaining nine months of FY27.

What's Changed

• Consolidated quarterly revenue rose to ₹2,545 crore in Q1 FY27 from ₹2,167 crore in Q1 FY26, a growth of 17.5% YoY.
• Consolidated operating EBITDA increased to ₹568 crore in Q1 FY27 compared to ₹491 crore in Q1 FY26.
• Hospital business revenue surged 19% YoY to ₹2,187 crore from ₹1,838 crore in Q1 FY26.

Key Takeaways

• Reiterated long-term margin target of 25% by FY28, which includes absorbing quarterly ESOP costs of approximately ₹50 crore.
• Expanding bed capacity by adding 400 beds in the remaining quarters of FY27, with 200 beds coming from the Fortis Memorial Research Institute (FMRI) facility.
• Agilus Diagnostics, the diagnostics division, is targeting a stable 12-13% revenue growth and 24-25% EBITDA margins for the rest of FY27.
• Strategic investment of ₹252 crore approved for a state-of-the-art Proton therapy facility at Gurugram to drive specialized oncology services.

SAHI Perspective

Fortis Healthcare is executing a balanced growth-and-efficiency strategy. By aggressively ramping up underperforming newer units like Manesar and Noida (which are currently operating at sub-10% EBITDA margins) and adding high-yield specialties like oncology through the ₹252 crore Proton facility, the company is systematically addressing margin dilution. While near-term profitability faces minor pressure from ESOP costs and new bed commissioning, the structural improvements in government and TPA collections should reinforce cash flows.

Market Implications

The healthcare sector continues to benefit from strong operating parameters like rising Average Revenue Per Occupied Bed (ARPOB). Fortis's focus on expanding in existing high-density clusters (Delhi NCR, Bengaluru, Mumbai) rather than entering highly competitive new territories reduces capital risk. This disciplined expansion, combined with steady pricing power, is likely to be viewed positively by long-term institutional investors looking for structural growth in Indian healthcare.

Trading Signals

Market Bias: Bullish

Robust 17.5% YoY revenue growth in Q1 FY27 coupled with a clear, realistic pathway to 25% EBITDA margins by FY28 provides a strong fundamental backstop. The operationalization of 400 beds and a ₹252 crore CapEx layout for specialized oncology (Proton therapy) are key growth triggers.

Overweight: Hospitals, Healthcare Delivery

Trigger Factors:

• Successful ramp-up and EBITDA transition of Manesar, Noida, and FMRI facilities
• Improvement in overall occupancy levels towards 70%+
• Stabilization of quarterly ESOP expenses
• Sustained 12-13% revenue growth in the Agilus diagnostic business

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian hospital sector is witnessing a major wave of brownfield capacity expansion, driven by robust demand, rising insurance penetration, and medical tourism. Competitors like Max Healthcare and Apollo Hospitals are also expanding capacities in similar major clusters. Fortis's cluster-focused model allows it to leverage regional brand equity and clinical talent, helping to shorten the gestation period for new beds compared to greenfield projects.

Key Risks to Watch

• Gestation drag from newly commissioned or acquired facilities (such as Manesar and Noida) if they remain at sub-10% margins for longer than expected.
• Higher-than-anticipated stock-based compensation (ESOP) costs putting pressure on near-term operating margins.
• Regulatory changes regarding hospital pricing or diagnostic service tariffs in India.

Recent Developments

During the Q1 FY27 earnings release, the board approved a capital expenditure of ₹252 crore for setting up a Proton therapy facility at its Gurugram hospital to strengthen its advanced oncology treatment portfolio.

Closing Insight

Fortis Healthcare's dual engine of steady hospital occupancy and a high-margin diagnostic franchise position it well for the next phase of Indian healthcare expansion. If the management successfully navigates the near-term margin headwinds from ESOPs and new bed commissioning, the targeted 25% EBITDA margin by FY28 is highly achievable, making it a compelling compounder in the hospital space.

High Performance Trading with SAHI.